Fortress Biotech Inc.

12/15/2020 | Press release | Distributed by Public on 12/15/2020 07:08

Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease